Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
What gemtuzumab regimen and schedule (with standard 7 plus 3) would you use for a newly diagnosed AML patient with favorable genetics?
Answer from: Medical Oncologist at Academic Institution
Per the ALFA-0701 trial, we administer GO (3 mg/m2, capped at 4.5 mg vial) on days 1,4, and 7 of induction therapy with 7+3.
Sign in or Register to read more
9930
Related Questions
In patients with HTLV-1 associated acute T-cell leukemia, is there any clear benefit of adding antivirals?
How should one approach an incidentally found T-cell gene arrangement?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
How has your approach to utilizing MRD-guided therapy in previously untreated CLL changed since the FLAIR trial, particularly in choosing between continuous versus time-limited treatment?
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?
How would you manage an elderly patient with mild pancytopenia who refuses bone marrow biopsy and whose flow cytometry is suggestive of CMML/MDS?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?